According to research report Healthcare Middleware Market is expected to reach USD 3.07 Billion by 2023 from USD 1.90 Billion in 2018, at a CAGR of 10.0%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258951459 Increasing utilization of smart devices, availability of big data in healthcare, increasing need for data interoperability, and growing investments to overcome healthcare interoperability issues are the key drivers of the global market for middleware in healthcare.In 2018, North America to dominate the healthcare middleware market In 2018, North America is expected to command the largest share of the market, followed by Europe, Asia, and the Rest of the World.The large share of North America is attributed to factors such as the implementation of federal health mandates to encourage the adoption of HCIT solutions, rising pressure to curb healthcare costs, increasing investment to improve data interoperability, and the growing adoption of smart devices.Based on application, the clinical application segment is expected to register the highest CAGR during the forecast period Based on application, the healthcare middleware market is segmented into clinical, financial, and operational and administrative applications.The clinical applications segment is expected to account for the largest share of the healthcare middleware market and is projected to register the highest CAGR during the forecast period.
According to research report the global Genome Engineering Market is projected to reach USD 6.28 billion by 2022 from USD 3.19 billion in 2017, at a CAGR of 14.5% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000The key factors propelling the growth of this genome editing market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.In 2017, North America is projected to have the highest growth rate during the forecast period.Factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding are propelling market growth in North America.The global genome editing market, by application, is segmented into cell line engineering, genetic engineering, and other applications (diagnostics and therapeutics).The cell line engineering segment is estimated to register the highest growth rate during the forecast period.Factors such as increasing funding from governments and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the cell line engineering segment.Based on end user, the global genome engineering market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations.The biotechnology & pharmaceutical companies’ segment is estimated to register the highest growth rate during the forecast period.The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.Based on technology, the genome engineering market is segmented into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In).
According to research report wearable healthcare devices market size is projected to reach USD 46.6 billion by 2025 from USD 18.4 billion in 2020, at a CAGR of 20.5% from 2020 to 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973 This market is largely driven by the increasing awareness of fitness and healthy lifestyles, development of technologically advanced products, growing geriatric population and subsequent increase in the incidence of chronic diseases, cost-containment in healthcare delivery, robust penetration of 3G and 4G networks for uninterrupted healthcare services, increasing penetration of smartphones and the growing number of smart-phone based healthcare apps and growing preference for wireless connectivity among healthcare providers are driving the growth of the global wearable healthcare devices industry.Growing adoption of mobile platforms, increasing adoption of AI and 5G, and the growing awareness & preference for home healthcare are opening opportunities for the growth of the market.In 2019, North America accounted for the largest share of 38.0% of the global wearable medical devices market.In 2019, the general health and fitness segment accounted for the largest share of the market, primarily due to the increasing focus on physical fitness among people to improve their quality of life, coupled with the growing trend of tracking health progress on a continuous basis.In 2019, the diagnostic & monitoring devices segment accounted for a larger share of 64.3% of the wearable medical devices market.
According to research report the global In Vitro Diagnostics Quality Control Market is projected to reach USD 1,158 million by 2025 from USD 961 million in 2020, at a CAGR of 3.8% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582Key players are focusing on increasing their presence in this growing market through both organic as well as inorganic growth strategies, such as product launches, agreements, partnerships, collaborations, and expansions.Due to the intense competition in the In Vitro Diagnostics Quality Control Market, various market players are increasingly focusing on expanding their geographic presence in high-growth emerging markets.Bio-Rad Laboratories Inc. (US) was the leading player in the In Vitro Diagnostics Quality Control Market and accounted for the largest share in 2018.The company is a leading provider of clinical diagnostic systems, analytical devices, and instruments.The company has a robust portfolio of quality control products, data management solutions and quality assurance services for hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories.For instance, in May 2019, the company launched InteliQ and Load-and-Go Tubes for quality controls to streamline the laboratory workflow.With this new launch the company enabled to strengthen its chemistry and immunoassay quality controls offerings.Randox Laboratories Ltd. (UK) held the second-largest share of the global IVD quality control market.
According to market research report the global Coagulation Analyzer Market is projected to reach USD 5.0 billion by 2025 from USD 3.8 billion in 2020, at a CAGR of 5.7% between 2020 and 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392 North America is the largest regional market for coagulation analyzers North America (comprising the US and Canada) accounted for the largest share of the global Coagulation Analyzer Market in 2019, followed by Europe.Factors such as the increasing prevalence of lifestyle diseases and the rising incidence of blood disorders are stimulating the growth of the market in North America.Clinical laboratory analyzers dominated the Coagulation Analyzer Market in 2019 Based on product, the Hemostasis Analyzer Market is segmented into clinical laboratory analyzers and point-of-care testing analyzers.In 2019, the clinical laboratory analyzers segment accounted for a larger share of the market.The large share of this segment can be attributed to factors such as the growing prevalence of blood disorders and increasing development of automated coagulation systems with faster turnaround times, compact size, and expanded capabilities.
Ask For Free PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=1152 The growth of this Weight Loss Management Market is majorly attributed to the growing rate of obesity, increasing prevalence of lifestyle diseases, and increasing number of bariatric surgeries.North America to dominate the weight loss and weight management market In 2017, North America is expected to dominate the global Weight Loss Management Market primarily due to factors such as the increasing incidence of obesity and chronic diseases, rising awareness about nutrition and healthy lifestyles, and growing number of fitness centers in the region.Ethicon, Inc. (U.S.), Covidien plc (U.S.), Apollo Endosurgery (U.S.), and Olympus Corporation (Japan) are some of the prominent players in the equipment market, while Brunswick Corporation (U.S.), Amer Sports (Finland), Johnson Health Technology, Ltd. (Taiwan), Cybex International (U.S.), and Technogym SpA (Italy) are the leading players in the fitness equipment segment.The prominent players in the services market are Weight Watchers International, Inc. (U.S.), Jenny Craig (U.S.), eDiets.com (U.S.), VLCC Healthcare Ltd. (India), Slimming World (U.K.), The Gold’s Gym International (U.S.), Duke Diet & Fitness Center (U.S.), 24 hours Fitness (U.S.), Equinox, Inc. (U.S.), Life Time Fitness, Inc. (U.S.), Fitness First Group (U.S.), and Town Sports International Holdings, Inc. (U.S.).The weight loss and weight management market are divided into various segments.For instance, the weight loss and weight management by surgical equipment was led by Ethicon, Inc. (U.S.) in 2013.
According to the new market research report Immunoassay Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.Ask For Free PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436The increasing incidence of chronic and infectious diseases, technological advancements in immunoassay instruments and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical industries are some the major factors driving the growth of this market.North America held the largest share of the market in 2017Based on region, the immunoassay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.North America dominated the market in 2017.The large share of this regional segment is attributed to the increasing incidence of chronic diseases and improved healthcare infrastructure.The chemiluminescence immunoassays (CLIAs) segment led the immunoassay market in 2017By platform, this market is classified into CLIAs, radioimmunoassays (RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms.The CLIAs segment accounted for the largest share of the immunoassay market in 2017.The large share of this segment can primarily be attributed to the low cost and high sensitivity of CLIA-based tests.By product and service, the reagents and kits segment commanded the largest share of the market in 2017On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services.In 2017, the reagents and kits segment accounted for the largest share of the immunoassay systems market.
According to research report the global cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.North America was the largest regional market for cancer biomarkers in 2016North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe.North America is the largest market for cancer biomarkers majorly due to government support (in the US and Canada) for the discovery and development of biomarkers, rising use of biomarkers in drug discovery and development by pharmaceutical companies, adoption of advanced omics technologies for biomarker discovery, and the increasing demand for personalized medicine in the region.The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast periodBased on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers).During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers).The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast periodBased on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers).
According to the new market research report Life Science Analytics Market is expected to reach 42.0 billion by 2025 from USD 22.1 billion in 2020, at a CAGR of 13.7% during the forecast period of 2020 to 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653Growth in this life science analytics software market is mainly driven by technological advancements, big data in the life science industry, growing adoption of analytics solutions in clinical trials, increasing adoption of analytics for sales & marketing applications, need for improved data standardization, increasing prevalence of chronic diseases, growing pressure to curb healthcare spending, and the need for improved patient outcomes.On the other hand, high implementation costs are expected to restrain the growth of this market to a certain extentThe life science analytics market is a highly diversified and competitive market, with a large number of players, including mid-tier companies and startup firms, competing for market shares.SAS Institute, Inc. (US), IBM Corporation (US), Oracle Corporation (US), Quintiles, Inc. (US), Accenture (Ireland), Cognizant (US), Wipro (India), MaxisIT, Inc. (US), TAKE Solutions (India), and SCIO Health Analytics (US) are some of the key players in this market.These players have adopted various growth strategies, such as product launches & upgrades; expansions; mergers & acquisitions; and partnerships, agreements, and collaborations, to further expand their presence in the global life science analytics software market.Some of the leading players who adopted these strategies are SAS Institute (US), Wipro Limited (India), Accenture (Ireland), IBM Corporation (US), and IQVIA (US).IBM Corporation (US)IBM Corporation is one of the leading players in the life science analytics market.The company focuses on inorganic as well as organic growth strategies such as acquisitions, collaborations, expansions, and product launches in order to expand its existing product portfolio and strengthen its market position.
According to the new market research report Spatial Genomics Market is projected to reach USD 404 million by 2025 from USD 178 million in 2020, at a CAGR of 17.8% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170900551The market growth is largely driven by the increasing adoption of spatial genomics and transcriptomics analysis among small companies and startups, expanding applications in biomarker identification and drug discovery & development, and increasing investment in biopharmaceutical RSpatial Transcriptomics techniques accounted for the largest share of the spatial genomics marketBased on the technique, the spatial genomics and transcriptomics market is segmented into spatial transcriptomics techniques and spatial genomics analysis techniques.In 2019, the spatial transcriptomics techniques segment accounted for the largest share of the global spatial genomics market.Growth in this market segment can be attributed to the increasing demand for and high adoption rate of in situ sequencing techniques.Academic & Research Institutes is the fastest-growing end-user segment of the marketBased on end-users, the spatial genomics market is segmented into academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies.In 2019, the academic & research institutes segment accounted for the largest share of the transcriptomics market.Market growth can largely be attributed to the increase in research intensity in this end-user segment and the availability of sufficient grants and funds for research.North America accounted for the largest share of the spatial genomics marketNorth America held the largest share in the global market, followed by Europe, with a share of 21.6%.The large share of the North American regional segment can be attributed to the presence of well-established as well as emerging market players operating in the spatial genomics market in this region.10X Genomics (US), NanoString Technologies Inc. (US), Illumina Inc. (US), and Bio-Rad Laboratories (US) are the prominent players operating in the transcriptomics market.
According to the new market research report the global remote patient monitoring market is projected to reach USD 117.1 billion by 2025 from USD 23.2 billion in 2020, at a CAGR of 38.2% between 2020 and 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492The rising geriatric population and the growing need to expand healthcare access, cost benefits of telehealth and remote patient monitoring, benefits of RPM to reduce the burden on medical resources, advancements in telecommunications, growing incidences of chronic diseases, and increasing investments in telehealth and RPM are the major factors driving the growth of this market.However, the regulatory variations across regions, healthcare fraud, and informal usage of social media practices is expected to restrain the market growth during the forecast period.The prominent players operating in the remote patient monitoring market include BioTelemetry Inc. (US), Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), GE Healthcare (US), Cerner Corporation (US), Siemens Healthineers AG Germany, OMRON Healthcare (Japan), Boston Scientific Corporation (US), Abbott Laboratories (US), Resideo Life Care Solutions (US), Vivify Health, Inc. (US), ALTEN Calsoft Labs (France), Preventice Solutions (US), Bio-Beat Technologies (Israel), VitalConnect (US), Welch Allyn (US), Teladoc Health Inc. (US), Dexcom Inc. (US), iRhythm Technologies, Inc. (US), and VivaLNK Inc.Players in this market focused on partnerships, collaborations, agreements, acquisitions, mergers, expansions, and product launches & approvals to expand their market presence between January 2017 and July 2020.KONINKLIJKE PHILIPS N.V. (NETHERLANDS)Koninklijke Philips N.V. (Netherlands) is the leading player in the remote patient monitoring market.The company’s expertise, experience, and comprehensive capabilities in various industries and business functions enable it to maintain its leading position in the market.The company focuses on achieving sustainable growth by enhancing its operating base and launching competitive technologies.In 2020, Philips launched the Avalon CL Fetal and Maternal Pod and Patch for remote monitoring in the US, Europe, Australia, New Zealand, and Singapore to support fetal & maternal monitoring.
According to research report Extracorporeal Membrane Oxygenation Machine Market is expected to reach USD 305.3 Million by 2021 from USD 247.2 Million in 2016, at a CAGR of 4.3%.Ask For Free PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=255167654A number of factors such as the growing cardiovascular and respiratory diseases, rising adoption of ECMO as a bridge to heart & lung transplantation, growing number of ECMO centers, conferences and training programs to increase awareness, and technological advancements are the significant factors driving the growth of the Extracorporeal Membrane Oxygenation Machine Market.Bleeding mainly occurs due to a drug called Heparin, which is used for blood thinning.According to a study published by NCBI in 2013, about 23% of patients undergoing ECMO suffered severe bleeding.According to a study conducted by NCBI, bloodstream infection was one of the most common complications occurring in ~14.4% of patients on ECMO.• Technical Failures: Air within the ECMO circuit causes up to 4% of mechanical failures.Pump failures are caused due to motor malfunction or power outage as well as inadequate venous return.
According to research report the Blood Gas and Electrolyte Analyzer Market was estimated to be USD 506.9 Million in 2016, which would reach USD 636 Million by 2021, growing at a CAGR of 4.6% during 2016 to 2021.Ask For Free PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963A number of factors, such as the growing number of patients being treated in ICUs, NICUs, and emergency departments, and the increasing adoption of technologically advanced biosensors and data analysis software for developing next-generation blood gas analyzers are expected to drive the growth of the blood gas analyzer market in the coming years.The other factors driving the growth of Blood Gas and Electrolyte Analyzer Market include rising geriatric population and the subsequent increase in the prevalence of chronic diseases, increasing adoption of technologically advanced biosensors and data analysis software, growing demand for technology integrated combined systems, and miniaturization of POC blood gas analyzers.North America is expected to account for the largest blood gas analyzer market share in 2016, which is primarily attributed to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives in this region.However, the APAC Blood Gas Analyzers market is projected to witness a higher growth during the forecast period due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures.The Blood Gas and Electrolyte Analyzer Market is segmented on the basis of major product brands (i-STAT, epoc, GEM 3000, GEM 3500, GEM 4000, ABL800, ABL80, ABL90, cobas b 221, cobas b 121, cobas b 123, RAPID Series) in four major regional segments, namely, North America, Europe, APAC, and Rest of the World.This report analyzes the market from both value and volume perspectives.GEM 3000 is expected to account for the largest share of the global blood gas analyzers market in 2016.This is mainly because GEM 3000 delivers real-time system diagnostics, requires low labor-intensive system calibration, and eliminates lengthy equipment training and possible human errors.
According to the new market research report eHealth Market is expected to reach USD 132.35 Billion by 2023 from USD 47.60 Billion in 2018, at a CAGR of 22.7%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11513143 Factors such as the growing need to manage regulatory compliance through the use of eHealth solutions, the need to curtail escalating healthcare costs, increasing government initiatives supporting the use of eHealth solutions and services, the high prevalence of chronic diseases, shift towards patient-centric healthcare delivery, and rising usage of big data are majorly driving the growth of this market.he Asia Pacific region is expected to register the highest growth rate in the global eHealth market during the forecast period.Growing medical tourism, growing consumerism in the healthcare industry, accelerated economic growth of countries in the region, the implementation of new ICT guidelines, and the implementation of eHealth programs are the factors propelling the growth of the market in this region.North America dominated the market in 2017In 2017, North America dominated the global eHealth market.The large share of this regional segment can be attributed to the region’s favorable regulatory scenario, the high adoption of eHealth solutions to curtail soaring healthcare costs, regulatory requirements regarding patient safety, and the presence of a large number of healthcare IT companies.Based on end user, the healthcare consumers segment is expected to register the highest CAGR during the forecast period.Factors such as the rising demand for personalized care, increased awareness for telehealth services, and high penetration of digital technologies among consumers are contributing to the high adoption of eHealth solutions among healthcare consumers.By type of eHealth solutions market, the chronic care management apps are expected to register the highest CAGR during the forecast period.This can be attributed to the growing incidence of chronic diseases, high penetration of mobiles, and increasing adoption of mHealth solutions owing to various benefits such as ease of use and reduced costs offered by these solutions across the globe.Based on product and service, the eHealth market is segmented into eHealth solutions and eHealth services.The eHealth services segment is expected to grow at the highest CAGR during the forecast period.
According to the new market research report RSV Diagnostics Market is expected to reach USD 929.2 Million by 2022 from USD 574.3 Million in 2017, at a CAGR of 10.1%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95683942 Factors driving the growth of this market include rising burden of RSV infections, growing demand for PoC molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays.North America is estimated to command the largest share of the market during the forecast period.Based on region, the Respiratory Syncytial Virus Diagnostics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).North America is estimated to dominate the RSV diagnostics market in 2017.This is mainly due to factors such as the increasing patient base of RSV diseases, technological advancements in PoC molecular diagnostic devices, and growing healthcare expenditures.Based on method, the market is segmented into molecular diagnostics, rapid antigen detection tests, and other methods.The molecular diagnostics segment is estimated to register the highest growth during the forecast period.Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=95683942Based on end user, the market is segmented into hospitals & clinics and home care.The hospitals and clinics segment is estimated to grow at the highest rate during the forecast period.
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894Market growth factors such as increasing adoption of target therapy over traditional therapy, emergence of biosimilars, increasing demand for mAbs, high prevalence of cancer.Cancer immunotherapy drugs are designed to alter or boost the body’s natural immune response to fight cancer this market is research-driven with a high degree of dependence on the discovery of molecules that can generate an immune response against various indications.Based on regions, the global Cancer Immunotherapy market is segmented into North America, APAC, Europe and the Rest of the World (RoW).North America is expected to account for the largest share of the market during the forecast period.Growth in this regional segment is driven by factors such as increase in patient pool, and initiative taken by the government for the development of Cancer Immunotherapy.In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region.On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators.The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021.The high growth in this segment is primarily attributed to the high success rate of these inhibitors.On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others.
According to the new market research report Clinical Microbiology Market is estimated to be USD 3.9 billion in 2020 and projected to reach USD 5.3 billion by 2025, at a CAGR of 6.5%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367Factors such as the Technological advancements, rising incidence of infectious diseases and growing outbreak of epidemics (such as COVID-19), and increased funding and public-private investments are some of the key factors driving the growth of the microbiological testing/clinical microbiology market.Other prominent players include Thermo Fisher Scientific (US), QIAGEN (Netherlands), 3M (US), Bio-Rad Laboratories (US), Bruker Corporation (US), and Hologic (US) are some of the major players in the clinical microbiology market among others.The analysis of market developments between 2017 and 2020 revealed several growth strategies such as research collaborations and strategic market expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the clinical microbiology market.bioMérieux is the leading player in the clinical microbiology market.The company has a robust product portfolio and a strong geographical presence in more than 160 countries.To maintain its leadership position in the market, the company has been focusing on R activities and product launches.In 2019, the company invested USD 60 million for setting up a production facility in Durham.
According to research report Surgical Microscopes Market is poised to reach USD 915.6 Million by 2021 from USD 508.1 Million in 2016, at a CAGR of 12.5% from 2016 to 2021.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179225920The increasing use of fluorescence image-guided surgery (FIGS), increase in the number of surgeries and growing demand for MIS, advancements in healthcare facilities, technological advancements, and customized microscopy solutions are the key factors driving the growth of the global surgical microscopes market.North America and Europe are established markets for surgical microscopes, due to broad technical applications of surgical microscopes and improved healthcare facilities in the region.However, Asia-Pacific is expected to show high growth rate in next few years in global operating microscopes market.This is due to presence of immense potential associated with healthcare services and increased investment in R Increasing healthcare awareness is also fuelling the growth of surgical microscopes market in emerging countries.China, India, Brazil, and the Middle East are the emerging markets for surgical microscopes; these markets are currently in the nascent stage.These markets lack proper standards and government regulations and offer a huge potential for providers unable to meet U.S. standards.PERSONALIZE THIS RESEARCH> Triangulate with your Own Data> Get Data as per your Format and Definition> Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor> Any level of PersonalizationGet 10% FREE Customization on This Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=179225920On the basis of application, the operating microscopes market is segmented into neuro and spine surgery, plastic and reconstructive surgery, ophthalmology, gynecology and urology, oncology, dentistry, ENT surgery, and documentation.In 2016, the neuro and spine surgery segment is expected to account for the largest share of the market due to the increasing demand for surgical/operating microscopes in neurosurgery.However, the oncology segment is expected to grow at the highest CAGR during the forecast period.
According to research report the pacemakers market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 2.0% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243344814A pacemaker is a medical device used when the heart is unable to produce electrical impulses naturally.When the heart’s natural pacemaker is defective or when the electrical pathways of the heart are blocked, it can cause irregular heartbeats, as known as arrhythmias.A pacemaker uses electrical pulses to prompt the heart to beat at a normal rate to treat arrhythmias.Recent Developments:• In November 2017, Medtronic received FDA approval and launched the Azure pacemaker with BlueSync technology in the US market• In February 2017, Medtronic received CE Mark certification for its Next Generation Cardiac Resynchronization Therapy-Pacemakers• In February 2017, Abbott Laboratories received FDA approval for the Assurity MRI Pacemakers• In March 2016, St. Jude Medical received the CE Mark certification for MRI compatibility for its Nanostim leadless pacemakersThe major players in the pacemakers market include Medtronic (Ireland), Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China).These players have adopted various growth strategies such as expansions, acquisitions, and new product launches to expand their presence in the global pacemakers market.This has helped them to expand their consumer base and address the unmet needs of end users.In line with rising adoption of pacemaker devices, Medtronic focus on to develop innovative products for the treatment of heart rhythm disorders and heart failures.
According to market research report Veterinary Dental Equipment Market is projected to reach USD 490 million by 2023 from USD 329 million in 2018, at a CAGR of 8.3% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155083837Growth in the global companion animal population, the rising incidence of veterinary dental problems, and growth in the number of veterinary practitioners and income levels in developed economies during the forecast period are the primary drivers for the Veterinary Dentistry Equipment Market during the forecast period.Recent Developments -In 2018, Dispomed (US) launched Highdent Quattro Plus, its latest in veterinary dental units.In 2018, Eickemeyer (Germany) signed a partnership agreement with Central CPD (UK) to connect with veterinary practitioners through professional training programs and promote the latest medical equipment.In 2015, Henry Schein (US) acquired Jorgen Kruuse A/S (Denmark) to expand the company's Animal Health business in 23 countries with a strong presence in Nordic countries.iM3 is the leading player in the veterinary dental equipment market.iM3 is a family owned veterinary (exclusive) dental company, which was established in Sydney, Australia over two decades ago.From its three locations in Sydney (Australia), Vancouver WA (US), and County Meath (Ireland), iM3 supplies high-quality, affordable veterinary dental products across the world.The company designs, develops, and manufactures dental machines, instruments, X-rays systems, and dental consumables.Moreover, it also provides a wide range of educational material for the dental veterinary community.North America to dominate the Veterinary Dental Equipment Market in 2018North America is expected to account for the largest share of the Veterinary Dental Instruments Market in 2018, followed by Europe and the Asia Pacific.